RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-drug conjugate targeting HER3. Here, RR 39%, mPFS 8.2m with efficacy across different mechanisms of TKI resistance. @OncoAlert #LCSM ht
RT @NatRevClinOncol: In a phase I trial involving 57 pts with EGFR TKI-resistant NSCLC, the anti-HER3 ADC patritumab deruxtecan induced obj…
RT @NatRevClinOncol: In a phase I trial involving 57 pts with EGFR TKI-resistant NSCLC, the anti-HER3 ADC patritumab deruxtecan induced obj…
In a phase I trial involving 57 pts with EGFR TKI-resistant NSCLC, the anti-HER3 ADC patritumab deruxtecan induced objective responses in 39%, independent of the EGFR TKI resistance mechanism or HER3 membrane expression level; mPFS was 8.2 months: https://
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
🚨🫁 Development in progress for #EGFR mNSCLC post-TKI ➡️ Patritumab Deruxtecan IV Q3W Ph1 study just published and interesting results : ➡️ORR 39% ➡️mPFS 8.2mths ☣ Manageable toxicity To follow !
RT @drgandara: Yes @StephenVLiu Patri HER3 ADC data are encouraging but how does it actually work? As an ADC, is this a “wolf in sheep’s cl…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
New article: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer https://t.co/s8MnRNVlU0 #lungcancer #oncology https://t.co/I27K3ZlImh
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
Yes @StephenVLiu Patri HER3 ADC data are encouraging but how does it actually work? As an ADC, is this a “wolf in sheep’s clothing”? https://t.co/wHLAty8RzV
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @CD_AACR: Just published #OnlineFirst: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutat…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @StephenVLiu: Available @CD_AACR: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mu…
RT @CD_AACR: Just published #OnlineFirst: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutat…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mut…
RT @CD_AACR: Just published #OnlineFirst: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutat…
RT @PTarantinoMD: Just out on @CD_AACR ph1 data of Patritumab-DXd (HER3-DXd) in EGFR mutant NSCLC 👉Among 57 patients, ORR was 39% and mPFS…
RT @PTarantinoMD: Just out on @CD_AACR ph1 data of Patritumab-DXd (HER3-DXd) in EGFR mutant NSCLC 👉Among 57 patients, ORR was 39% and mPFS…
RT @CD_AACR: Just published #OnlineFirst: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutat…
RT @PTarantinoMD: Just out on @CD_AACR ph1 data of Patritumab-DXd (HER3-DXd) in EGFR mutant NSCLC 👉Among 57 patients, ORR was 39% and mPFS…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mut…
RT @PTarantinoMD: Just out on @CD_AACR ph1 data of Patritumab-DXd (HER3-DXd) in EGFR mutant NSCLC 👉Among 57 patients, ORR was 39% and mPFS…
Just out on @CD_AACR ph1 data of Patritumab-DXd (HER3-DXd) in EGFR mutant NSCLC 👉Among 57 patients, ORR was 39% and mPFS 8.2 months 👉mOS n.r. after 10 months ❗️ILD rate was 6%, with 1 G5 event Very interesting compound, eager to see more data in BC htt
Just published #OnlineFirst: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by Pasi Janne and colleagues. https://t.co/H7Lg36qOhX. @DanaFarber @DaiichiSankyoUS https://t.co/HL
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mut…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mut…
RT @HarmonyTurk: Related clinical trial online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Res…
RT @HarmonyTurk: Related clinical trial online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Res…
Related clinical trial online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by #ESMO21 co-chair Pasi Janne & co @DanaFarber @DaiichiSankyoUS #clinicaltrial ht
⭐️Now online in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by #ESMO21 Scientific co-chair Pasi Janne and colleagues @DanaFarber @DaiichiSankyoUS #clinicaltrial h